Tests oral LW402 tablets for moderate-to-severe atopic dermatitis
Tests oral LW402 tablets against placebo in adults with moderate-to-severe atopic dermatitis.
Plain-language title generated from the registry record
Registry title: Evaluation of the Efficacy and Safety of Oral LW402 Tablets for the Treatment of Patients With Moderate-to-Severe Atopic Dermatitis
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07370909, who can take part
Where in China
- Peking University People's HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shanghai Longwood Biopharmaceuticals Co., Ltd.
- Trial code
- NCT07370909
- Record updated
- 27 August 2026
- Original description
This Phase 3, double-blind (sponsor-open), multicenter, placebo-controlled study aims to evaluate the efficacy and safety of oral LW402 tablets in patients with moderate to severe atopic dermatitis.Read full original descriptionShow less
A Multi-center, Randomized, Double Blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of LW402 Tablets in Patients With Moderate-to-severe Atopic Dermatitis.
This Phase 3, double-blind (sponsor-open), multicenter, placebo-controlled study aims to evaluate the efficacy and safety of oral LW402 tablets in patients with moderate to severe atopic dermatitis.
Inclusion: Subjects voluntarily provided informed consent and agreed to participate in the study; Gender: no restrictions; Age: 18 to 75 years inclusive (as of the date of signing the informed consent form); At screening, subjects met the Hanifin-Rajka diagnostic criteria for atopic dermatitis (AD) (Appendix 4) and had a documented AD history of ≥1 year prior to screening; At screening and baseline visits, subjects were required to have moderate-to-severe atopic dermatitis (AD) with all three of the following criteria satisfied:; Total AD lesion area ≥ 10% of body surface area (BSA); Investigator's Global Assessment (IGA) score ≥ 3; Eczema Area and Severity Index (EASI) score ≥ 16.
Exclusion: Subjects with a documented history of hypersensitivity to Janus kinase (JAK) inhibitors; Subjects with current or a history of autoimmune diseases other than atopic dermatitis (AD) (e.g., systemic lupus erythematosus [SLE], inflammatory bowel disease [IBD], Felty's syndrome, scleroderma, inflammatory myopathy, other connective tissue diseases, overlap syndrome) or other skin conditions that may interfere with AD assessment (e.g., contact dermatitis, psoriasis).